Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis-Reference-Cited by-同舟云学术

Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis

Published:2017-12 Issue:S1 Volume:6 Page:S21-S34
ISSN:2218-6751
Container-title:Translational Lung Cancer Research
language:
Short-container-title:Transl. Lung Cancer Res.

Author:

González-Larriba José Luís,Lázaro-Quintela Martín,Cobo Manuel,Dómine Manuel,Majem Margarita,García-Campelo Rosario

Publisher

AME Publishing Company

Subject

Oncology

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of Epidermal Growth Factor Receptor Signaling by Antisense Oligonucleotides as a Novel Approach to Epidermal Growth Factor Receptor Inhibition;Nucleic Acid Therapeutics;2022-10-01

2. The utility of transbronchial rebiopsy for peripheral pulmonary lesions in patients with advanced non-squamous non-small cell lung cancer;BMC Pulmonary Medicine;2020-09-09

3. Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation;Cancer Biology & Therapy;2020-06-16

4. Compared to plasma, bronchial washing fluid shows higher diagnostic yields for detecting EGFR-TKI sensitizing mutations by ddPCR in lung cancer;Respiratory Research;2020-06-09

5. PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations;Scientific Reports;2019-04-05